[Adverse drug reactions induced by molecular target therapy].
Kano
Yoko
Y
Department of Dermatology, Kyorin University School of Medicine.
D000707:Anaphylaxis / Q000139:chemically induced; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001549:Benzamides; D000068818:Cetuximab; D003141:Communicable Diseases / Q000139:chemically induced; D066246:ErbB Receptors; D000068800:Etanercept; D016044:Fusion Proteins, bcr-abl; D000077156:Gefitinib; D006801:Humans; D000068877:Imatinib Mesylate; D007074:Immunoglobulin G / Q000009:adverse effects*; D000069285:Infliximab; D008171:Lung Diseases / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases; D011743:Pyrimidines / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*; D018124:Receptors, Tumor Necrosis Factor; D012871:Skin Diseases / Q000139:chemically induced; D014409:Tumor Necrosis Factor-alpha
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001549:Benzamides; D007074:Immunoglobulin G; D010879:Piperazines; D011743:Pyrimidines; D011799:Quinazolines; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068877:Imatinib Mesylate; D000069285:Infliximab; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D000068800:Etanercept; D000068818:Cetuximab; D000077156:Gefitinib